{
  "docId": "019de070-2277-75da-968a-7dffc3addc7d",
  "docSlug": "9a22f83671fc7371cae4ff7d98099963",
  "documentTitle": "Fusion Pharmaceuticals | IPO Presentation Deck | 49 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 49,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Uses a funnel diagram to illustrate the R&D process steps.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-2277-75da-968a-7dffc3addc7d/18",
  "deckHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d",
  "deckJsonHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d.json",
  "deckAnchorHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.3,
        "x": 0.65,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Funnel showing conversion of AVE-1642 to FPI-1434 through Radiolabel, Assess Target Binding in vitro, Biodistribution in Tumor Model, and 30 Day Efficacy Study.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b67790cf-ee80-46e6-9eec-9dae97e7aea4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "Antibody originally developed by Sanofi (AVE-1642). Sanofi licensed from Immunogen as a therapeutic. Humanized IgG1 monoclonal antibody. AVE-1642 reached Phase 2 and was discontinued / returned to Immunogen due to lack of efficacy. Approximately 140 patients received AVE-1642 in clinical trials. Fusion licensed AVE-1642 (now identified as FPI-1175) from Immunogen in 2016. Fusion received nonclinical and CMC information along with GMP cell bank.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57349065-61ce-4c92-b4fa-faa687b59e9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Fusion's R&D Team Converted AVE-1642 Into A New TAT, FPI-1434",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b20ec22-5a1b-4c57-97dc-6c112a7028ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Developing a TAT Targeting IGF-1R",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f808edb1-0ecb-4198-92f2-dc8c67f826f3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "6d945dc0-9d0e-4924-bb33-e40c615e50eb",
      "evidence": "Funnel showing conversion of AVE-1642 to FPI-1434 through Radiolabel, Assess Target Binding in vitro, Biodistribution in Tumor Model, and 30 Day Efficacy Study",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "2174dc82-af52-4878-9e3d-c693e3d6fc7e",
      "evidence": "Funnel diagram illustrating R&D steps",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 15,
      "beatId": "7bd0078a-c933-4fb9-99e7-f9dff4a4cc20",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines Fusion Pharmaceuticals' development opportunities and future milestones.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}